MLN9708: Phase I data

In a dose-escalation Phase I trial in 18 patients, IV MLN9708 was generally well tolerated up to 1.76 mg/m 2. There was 1 dose-limiting toxicity (DLT) of grade 3 rash in patients receiving 1 mg/m 2 ML...